Evidence map›Paper›PMID 38852161›Full record

ArticleOral diseases2025

Salivary calprotectin and neutrophils in inflammatory bowel disease in relation to oral diseases.

Mirjam Majster, Sven Almer, Sebastian Malmqvist, Annsofi Johannsen, Ronaldo Lira-Junior, Elisabeth Almer Boström

Abstract read
In one paragraph

Article in Oral diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mirjam MajsterDivision of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Sven AlmerDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Sebastian MalmqvistDivision of Oral Diseases, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Annsofi JohannsenDivision of Oral Diseases, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Ronaldo Lira-JuniorDivision of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Elisabeth Almer BoströmDivision of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1788-7501

Funding

Karolinska Institutet FoundationsRegion Stockholm FoUI-954341, FoUI-977161Swedish Dental SocietyThe Center for Innovative Medicine (CIMED) FoUI-954540The Ihre FoundationThe Patent Revenue Fund for Research in Preventive OdontologyThuréus Foundation
6 · The paper itself

Abstract

objectiveCalprotectin is elevated in saliva from inflammatory bowel disease (IBD) patients, but it is also affected by oral disease. We assessed the salivary concentration of calprotectin in IBD patients, in relation to intestinal and oral diseases. Furthermore, we investigated the phenotype of salivary neutrophils from IBD patients, and their ability to secrete calprotectin. MATERIALS AND

methodsThirty IBD patients and 26 controls were orally examined and sampled for stimulated saliva. Twenty-five IBD patients provided fresh fecal samples. Calprotectin concentrations in saliva and feces were determined by an enzyme-linked immunosorbent assay. Expression of CD11b, CD15, and CD16 on oral neutrophils was assessed by flow cytometry. Secretion of calprotectin was evaluated in cultured oral neutrophils.

resultsCalprotectin was significantly elevated in saliva of IBD patients compared to controls, particularly in Crohn's disease, irrespective of caries or periodontitis. Salivary calprotectin did not correlate to fecal calprotectin. CD11b expression was significantly reduced in salivary neutrophils from IBD patients. Salivary neutrophils from IBD patients tended to secrete more calprotectin than controls.

conclusionsSalivary calprotectin is elevated in IBD regardless of oral diseases. Furthermore, salivary neutrophils secrete calprotectin, and display lower CD11b expression in IBD.

Indexed as

Inflammatory Bowel DiseasesLeukocyte L1 Antigen ComplexMouth DiseasesNeutrophilsSalivaAdultAgedCase-Control StudiesCD11b AntigenCrohn DiseaseFecesFemaleFlow CytometryHumansMaleMiddle AgedCD11b AntigenLeukocyte L1 Antigen ComplexReceptors, IgGcalprotectincariesinflammatory bowel diseaseneutrophilsperiodontitissaliva

Identifiers

PMID38852161
PMCPMC11808171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.